15:44 - 15.07.2026

---

July 15, Fineko/abc.az. Johnson & Johnson reported better-than-expected results for the 2nd quarter: EPS of $2.90 (forecast $2.86), revenue of $25.31 billion (+6.6% y/y). The company also raised its forecast for 2026.

Despite the strong results, shares fell by nearly 1% in the premarket.

Growth was driven by the innovative medicine segment (oncology, immunology, and neuroscience), while some of the growth was offset by a decline in sales of certain drugs. The medical technology segment also showed moderate growth (+3.6%).